

AGENDA

POETIC Winter Meeting

March 6th – March 8th, 2024 University of Arizona College of Medicine – Phoenix Campus 435 N 5th St, Phoenix, AZ 85004

WEDNESDAY, MARCH 6, 2024

EVENING SESSION 4:00 PM MT (6:00 PM EST)	Health Sciences Education Building, 4 th Floor Room C403
3:30 – 4:00 PM	REGISTRATION
4:00 – 5:00 PM MT (6:00 – 7:00 EST)	PI MEETING (Closed Session)
5:00 – 7:00 PM MT (7:00 – 9:00 EST)	BOARD OF DIRECTORS MEETING (Closed Session)
7:15 – 8:15 PM	DINNER – PALO VERDE TREE SEATING AREA (HEALTH SCIENCES EDUCATION BUILDING) Open to all attendees (Non-Board of Directors, Non-PIs please RSVP)
8:15 PM	WALK BACK TO SPRINGHILL SUITES

THURSDAY, MARCH 7, 2024

MORNING SESSION 8:00 AM – 1:15 PM MT	Health Sciences Education Building, 4 th Floor Room C403
6:30 – 7:45 AM	BREAKFAST AT THE SPRINGHILL SUITES AT YOUR LEISURE
7:45 – 8:30 AM	WALK TO MEDICAL SCHOOL CAMPUS / REGISTRATION
8:30 – 8:35 AM	GREETINGS / INTRODUCTIONS Michael Henry, MD and Mallery Olsen, MD – POETIC Co-PIs - Center for Cancer and Blood Disorders, Phoenix Children's, Phoenix, AZ Norman Lacayo, MD - Director, POETIC; Lucile Packard, Stanford University
	KEYNOTE LECTURE
	Leveraging Biorepositories for Translational Research in Pediatric Osteosarcoma
8:35 – 9:15 AM	Michael Berens, PhD - Professor and Director, Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ
	Mona Nourani, MD – Center for Cancer and Blood Disorders, Phoenix Children's, Phoenix, AZ
9:15 AM – 12:15 PM	DEVELOPMENTAL THERAPEUTICS
9:15 – 9:40 AM	Autophagy: A Mechanism for Therapy Resistance in Pediatric Glioma Lindsey Hoffman, DO – Center for Cancer and Blood Disorders, Phoenix Children's, Phoenix, AZ
9:40 – 10:05 AM	Combine and Conquer: The Promise of Combination Therapies with FOXM1 Inhibitors for Rhabdomyosarcoma
	Nawal Merjaneh, MD – Center for Cancer and Blood Disorders, Phoenix Children's, Phoenix, AZ
10:05 – 10:30 AM	Identifying Target Neoantigens for Cancer Immunotherapy Skyler Henry, PhD – Postdoctoral Research Scholar, Biodesign Center for Personalized Diagnostics, Arizona State University, Tempe, AZ
10:30 – 10:55 AM	TKI use in pediatric bone sarcomas: experience and future directions Mallery Olsen, MD – Center for Cancer and Blood Disorders, Phoenix Children's, Phoenix, AZ
10:55 – 11:25 AM	BREAK
11:25 AM – 12:15 PM	POETIC Solid Tumor Working Group (Update and discussion)
	Anne-Marie Langevin, MD - Professor of Pediatrics, Greehey Chair in Pediatric Oncology, UT Health San Antonio, TX
	Breakout session for research staff: HSEB C402
	Leveraging Advarra cIRB for POETIC studies Jenna Dotson, Clinical Regulatory Specialist, POETIC RDMC

12:15 – 1:15 PM	RUTH TAN LIM LECTURE SERIES: KEYNOTE SPEAKER
	Knowledge, Precision, or Certainty? Immersive Data Mining for Better Clinical Outcomes
	Daniel Catchpoole, PhD, Professor and Head of the Tumour Bank, Children's Hospital at Westmead, Sydney, Australia
1:15 – 1:25 PM	GROUP PICTURE: PALO VERDE TREE SEATING AREA (HEALTH SCIENCES EDUCATION BUILDING)
1:25 – 2:15 PM	LUNCH: PALO VERDE TREE SEATING AREA (HEALTH SCIENCES EDUCATION BUILDING)
AFTERNOON SESSION 2:15 – 5:00 PM MT	Health Sciences Education Building, 4 th Floor Room C403
2:15 – 5:00 PM	DEVELOPMENTAL THERAPEUTICS, CONTINUED
2:15 – 2:40 PM (Virtual session)	Gilead pipeline molecules with a pediatric perspective Anjali Sharma, MD – Pediatric Hematology/Oncology Global Development Lead, Gilead Sciences
2:40 – 3:05 PM	TGF-beta inhibition as a novel therapeutic option in osteosarcoma Allison Pribnow, MD – Lucile Packard, Stanford University, Palo Alto, CA Kristen VanHeyst, DO – Rainbow Babies and Children's Hospital, Cleveland, OH
3:05 – 3:30 PM	An overview of FDA guidance and legislation affecting pediatric drug development
(Virtual session) 3:30 – 3:45 PM	Nicole Drezner, MD – Deputy Director, Division of Oncology, FDA
3.30 – 3.45 I M	BREAK
3:45 – 4:10 PM	Developing ideas for next generation POETIC clinical trials Aru Narendran, MD, PhD, Alberta Children's Hospital, University of Calgary
	Targeting metabolic vulnerabilities for treating high-risk medulloblastoma
4:10 – 4:40 PM (Virtual session)	RNA demethylase as a novel target for improving immunotherapy response in osteosarcoma Manjeet Rao, PhD – Professor and Deputy Director, Greehey Children's Cancer Research Institute, UT Health San Antonio, TX
4:40 – 5:15 PM	 POETIC CNS Tumor Working Group (Update and discussion) Kevin Bielamowicz, MD, Arkansas Children's Hospital Breakout session for research staff: HSEB C402 Stuff To Say with Chris (Guided Discussion) Christopher Oless, RN – Oncology Research Nurse, Phoenix Children's
5:15 PM	WALK BACK TO SPRINGHILL SUITES

6:30 – 8:30 PM	DINNER – <u>THE VIG</u> (606 N. 4TH AVE, PHOENIX, AZ 85003)
6:15 PM	Shuttle bus service: Springhill Suites to The Vig
8:30 PM	Shuttle bus service: The Vig to Springhill Suites

FRIDAY, MARCH 8, 2024

Health Sciences Education Building, 4 th Floor Room C403
BREAKFAST AT THE SPRINGHILL SUITES AT YOUR LEISURE
WALK TO MEDICAL SCHOOL CAMPUS
International Children's Cancer Research Centre in Ghana
Tanya Trippett, MD, Co-Founder and Director Emeritus, POETIC; Memorial Sloan Kettering Cancer Center
A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium ¹⁷⁷ Lu- Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or in combination with Standard of Care (SoC) for the treatment of Somatostatin Receptor-positive Tumors in Pediatric Population (KinLET) Ayala Luria, PhD - ITM USA
DEVELOPMENTAL THERAPEUTICS, FOCUS ON HEMATOPOIETIC MALIGNANCIES
Total Therapy for Infants with Acute Lymphoblastic Leukemia, TINI 2 Study Tanja Gruber, MD - Lucile Packard, Stanford University
Talazoparib in Combination With Conventional Chemotherapy for AML, PARPAML trial (POE22-01) Jennifer Kamens, MD - Lucile Packard, Stanford University
CK2 inhibitor for treatment of AYAs with Relapsed/Refractory Leukemia Chandrika Gowda, MD - Penn State University
BREAK
Developing Resource-Adapted Treatment Guidelines for Childhood ALL Jessica Boklan, MD – POETIC Emeritus, World Health Organization / St. Jude's Children's Research Hospital

	POETIC Leukemia/Lymphoma Working Group (Update and discussion)
11:20 AM – 12:00 PM (Virtual session)	Spencer Mangum, MD - University of Utah, Huntsman Cancer Institute, Primary Children's Hospital
	Breakout session for research staff: HSEB C402
	Optimizing Adverse Event Capturing for POETIC Studies Tamar Shlapobersky PhD - Clinical Data Specialist, POETIC RDMC
	MEETING RECAP AND LUNCH (HSEB C401/C403)
12:00 – 1:00 PM	Michael Henry, MD and Mallery Olsen, MD - Center for Cancer and Blood Disorders, Phoenix Children's, Phoenix, AZ
	Norman Lacayo, MD - Director, POETIC; Lucile Packard, Stanford University
1:00 PM	
	MEETING ADJOURN